Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis
Open Access
- 23 July 2002
- Vol. 95 (3), 588-595
- https://doi.org/10.1002/cncr.10694
Abstract
BACKGROUND The prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is extremely poor. The aim of this study was to elucidate the efficacy of hepatic arterial infusion chemotherapy (HAIC) for patients with advanced HCCs. METHODS Forty‐eight HCC patients with PVTT were treated by HAIC via a subcutaneously implanted injection port. Of these, 14 had PVTT in the second portal branch and 34 patients had PVTT in the first portal branch or in the main portal trunk. One course of chemotherapy consisted of daily cisplatin (7 mg/m2 for 1 hour on Days 1–5) followed by 5‐fluorouracil (170 mg/m2 for 5 hours on Days 1–5). Patients were scheduled to receive four serial courses of HAIC. Responders were defined as having either a complete response (CR) or partial response (PR) and nonresponders were defined as exhibiting stable disease or progressive disease. The prognosis after HAIC and factors related to survival were analyzed. RESULTS Following HAIC, 4 and 19 patients exhibited a CR and PR, respectively (response rate = 48%). The 1, 2, 3, and 5‐year cumulative survival rates of 48 patients treated with HAIC were 45%, 31%, 25%, and 11%, respectively. Median survival periods for 23 responders and 25 nonresponders were 31.6 (range, 8.3–76.9) months and 5.4 (1.9–29.0) months, respectively. Therapeutic effect (P < 0.001) and hepatic reserve capacity (P = 0.021) were identified as significant prognostic factors by univariate analysis. Multivariate analysis identified only therapeutic effect as being significantly related to survival. CONCLUSIONS HAIC using low‐dose cisplatin and 5‐fluorouracil may be a useful therapeutic option for patients with advanced HCC with PVTT. HCC patients with PVTT who respond to HAIC could certainly have survival benefits. Cancer 2002;95:588–95. © 2002 American Cancer Society. DOI 10.1002/cncr.10694Keywords
This publication has 39 references indexed in Scilit:
- Randomized controlled trial of interferon treatment for advanced hepatocellular carcinomaHepatology, 2000
- Rising Incidence of Hepatocellular Carcinoma in the United StatesNew England Journal of Medicine, 1999
- Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trialsHepatology, 1999
- Treatment of hepatocellular carcinomaHepatology, 1997
- Microwave coagulation therapy for hepatocellular carcinomaGastroenterology, 1996
- CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation.American Journal of Roentgenology, 1995
- The Efficacy of Continuous Local Arterial Infusion of 5-Fluorouracil and Cisplatin through an Implanted Reservoir for Severe Advanced Hepatocellular CarcinomaOncology, 1995
- Liver Resection Versus Transplantation for Hepatocellular Carcinoma in Cirrhotic PatientsAnnals of Surgery, 1993
- Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapyHepatology, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958